Resilient Interim Results, Essex Bio-Technology Drives Growth and Innovation Essex Bio-Technology Limited Aug 26, 2025 20:00 HKT/SGT Read More
Mitsubishi Corporation Invests in Fullerton Health Mitsubishi Corporation Aug 26, 2025 11:54 HKT/SGT Read More
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab) Eisai Aug 25, 2025 18:30 HKT/SGT Read More
Lepu Biopharma (2157.HK) announces 2025 interim results Lepu Biopharma Co., Ltd. Aug 21, 2025 14:38 HKT/SGT Read More
樂普生物(2157.HK)公佈2025年中期業績 ADC管線多產品進入關鍵臨床階段 收入同比大增350% Lepu Biopharma Co., Ltd. Aug 21, 2025 14:23 HKT/SGT Read More
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration Essex Bio-Technology Limited Aug 13, 2025 20:24 HKT/SGT Read More
Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle CanSino Biologics Inc Aug 20, 2025 20:30 HKT/SGT Read More
Australian Breakthrough by Cholrem: Cyclodextrin Therapy Reverses Heart Disease, Hailed as Greatest Advance Since Statins Cholrem Pty Ltd Aug 19, 2025 21:00 HKT/SGT Read More
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers China Medical System Holdings Limited Aug 19, 2025 16:00 JST Read More
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers China Medical System Holdings Limited Aug 19, 2025 15:00 HKT/SGT Read More
康哲藥業(867.HK,8A8.SG)上半年營收淨利雙升 戰略轉型跑出增長新動能 China Medical System Holdings Limited Aug 19, 2025 11:53 HKT/SGT Read More
康哲药业(867.HK,8A8.SG)上半年营收净利双升 战略转型跑出增长新动能 China Medical System Holdings Limited Aug 19, 2025 11:53 HKT/SGT Read More
UNFPA and NEC Collaborate to Build Beneficiary Information Management and e-Voucher System NEC Corporation Aug 18, 2025 13:38 HKT/SGT Read More
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC Everest Medicines Limited Aug 15, 2025 20:15 HKT/SGT Read More
艾曲莫德入選《2025 ACG臨床指南:成人潰瘍性結腸炎》,獲強烈推薦用於中重度潰瘍性結腸炎的誘導緩解及維持緩解治療 Everest Medicines Limited Aug 15, 2025 20:07 HKT/SGT Read More
艾曲莫德入选《2025 ACG临床指南:成人溃疡性结肠炎》,获强烈推荐用于中重度溃疡性结肠炎的诱导缓解及维持缓解治疗 Everest Medicines Limited Aug 15, 2025 19:56 HKT/SGT Read More
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively OrbusNeich Medical Group Holdings Limited Aug 15, 2025 19:11 HKT/SGT Read More
業聚醫療2025年中期業績收入及純利雙雙增長 分別達8,360萬美元及1,980萬美元 OrbusNeich Medical Group Holdings Limited Aug 15, 2025 18:53 HKT/SGT Read More
业聚医疗2025年中期业绩收入及纯利双双增长 分别达8,360万美元及1,980万美元 OrbusNeich Medical Group Holdings Limited Aug 15, 2025 18:10 HKT/SGT Read More
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access Everest Medicines Limited Aug 14, 2025 18:00 HKT/SGT Read More